Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
100 GBX | +3.09% | -2.44% | -13.04% |
May. 14 | Headlam warns of loss; EnSilica predicts revenue rise | AN |
May. 14 | Celadon Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2021 | - | Sales 2022 | 0.02 | Capitalization | 31.14M |
---|---|---|---|---|---|
Net income 2021 | - | Net income 2022 | -17M | EV / Sales 2021 * | - |
Net cash position 2021 | 4.46M | Net cash position 2022 | 429K | EV / Sales 2022 | 1,279,759,792 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.71
x | Employees | 24 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 35.15% |
1 day | +3.09% | ||
1 week | -2.44% | ||
Current month | +2.04% | ||
1 month | -13.04% | ||
3 months | -9.09% | ||
6 months | -9.09% | ||
Current year | -13.04% |
Managers | Title | Age | Since |
---|---|---|---|
James Short
FOU | Founder | 55 | 17-12-31 |
Jonathan Turner
DFI | Director of Finance/CFO | 46 | 23-01-16 |
Iqbal Gill
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Firth
BRD | Director/Board Member | 62 | - |
Ian Anton
CHM | Chairman | 64 | 22-03-27 |
Robert Barr
BRD | Director/Board Member | 65 | 22-03-27 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 100 | +3.09% | 41,944 |
24-05-21 | 97 | +4.86% | 18,552 |
24-05-20 | 92.5 | -5.13% | 14,591 |
24-05-17 | 97.5 | -2.50% | 12,321 |
24-05-16 | 100 | -2.44% | 7,676 |
Delayed Quote London S.E., May 22, 2024 at 11:35 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-13.04% | 83.67M | |
+37.74% | 723B | |
+32.22% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+16.60% | 244B | |
+9.77% | 208B | |
-5.15% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- CEL Stock